Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2114)	1/14/2008 12:48:04 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

PARD Was up 23.65% on Friday bigcharts.marketwatch.com On Monday it announced that it had completed the enrollment for its PII on HRPC & abstracts had been accepted for ASCO GI and GU Symposia and SPEAR was on track for Top-Line data in 2008 - It provided an overview of its clinical goals for 2008 for picoplatin,which is its lead product candidate. (Picoplatin is a platinum-based chemo.) They will be presenting the data from the PI of picoplatin in patients with colorectal cancer at the ASCO 2008 Gastrointestinal Cancers Symposium,in Orlando by the end of this month. The insiders reportedly hold >35% & have been doing some buying lately.The stock seems to have support at the $4 level.PARD has been trimming some its losses. The EL in 2007 is around $1.10 vs.$1.32 in 2006. Th short ratio came down >10% in the last month, but still is > 13x the DAV. If the stock could get to test its June H at $8.95 it would be a good % gain from present levels.The March 200 H was $491.92 <g> bigcharts.marketwatch.com Bernard